Cargando…
Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome
Recent studies suggest that elevated CXCL13 serum levels in patients with primary Sjögren’s syndrome (pSS) associate with minor salivary gland (MSG) histologic features, disease severity, as well as high-risk status for non-Hodgkin lymphoma (NHL) development and NHL itself. In contrast, limited disc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416055/ https://www.ncbi.nlm.nih.gov/pubmed/34484201 http://dx.doi.org/10.3389/fimmu.2021.705079 |
_version_ | 1783748096931397632 |
---|---|
author | Chatzis, Loukas Goules, Andreas V. Stergiou, Ioanna E. Voulgarelis, Michael Tzioufas, Athanasios G. Kapsogeorgou, Efstathia K. |
author_facet | Chatzis, Loukas Goules, Andreas V. Stergiou, Ioanna E. Voulgarelis, Michael Tzioufas, Athanasios G. Kapsogeorgou, Efstathia K. |
author_sort | Chatzis, Loukas |
collection | PubMed |
description | Recent studies suggest that elevated CXCL13 serum levels in patients with primary Sjögren’s syndrome (pSS) associate with minor salivary gland (MSG) histologic features, disease severity, as well as high-risk status for non-Hodgkin lymphoma (NHL) development and NHL itself. In contrast, limited discriminative value of CXCL13 saliva levels has been reported. Prompt by these reports, we sought to validate the clinical utility of CXCL13 by investigating potential correlations of serum and saliva levels with MSG histopathologic [including CXCL13+-cell number, severity of infiltrates and germinal center (GC) formation], serologic and clinical parameters, as well as NHL. CXCL13 levels were evaluated in paired serum and saliva specimens of 45 pSS patients (15 with NHL; pSS-associated NHL: SSL), 11 sicca-controls (sicca-complaining individuals with negative MSG biopsy and negative autoantibody profile), 10 healthy individuals (healthy-controls) and 6 non-SS-NHLs. CXCL13+-cells were measured in paired MSG-tissues of 22 of pSS patients studied (including 7 SSLs) and all sicca-controls. CXCL13 serum levels were significantly increased in pSS and SSL patients compared to sicca- and healthy-controls and were positively correlated with the CXCL13+-cell number and biopsy focus-score. Serum CXCL13 was significantly higher in pSS patients with GCs, rheumatoid factor, hypocomplementemia, high disease activity, NHL and in high-risk patients for NHL development. CXCL13 saliva levels were significantly increased in SSL patients (compared to non-SS-NHLs), patients with GCs and in high-risk for NHL patients. Univariate analysis revealed that CXCL13 serum, but not saliva, levels were associated with lymphoma, an association that did not survive multivariate analysis. Conclusively, our findings confirm that serum, but not saliva, levels of CXCL13 are associated with histologic, serologic and clinical features indicative of more severe pSS. |
format | Online Article Text |
id | pubmed-8416055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84160552021-09-04 Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome Chatzis, Loukas Goules, Andreas V. Stergiou, Ioanna E. Voulgarelis, Michael Tzioufas, Athanasios G. Kapsogeorgou, Efstathia K. Front Immunol Immunology Recent studies suggest that elevated CXCL13 serum levels in patients with primary Sjögren’s syndrome (pSS) associate with minor salivary gland (MSG) histologic features, disease severity, as well as high-risk status for non-Hodgkin lymphoma (NHL) development and NHL itself. In contrast, limited discriminative value of CXCL13 saliva levels has been reported. Prompt by these reports, we sought to validate the clinical utility of CXCL13 by investigating potential correlations of serum and saliva levels with MSG histopathologic [including CXCL13+-cell number, severity of infiltrates and germinal center (GC) formation], serologic and clinical parameters, as well as NHL. CXCL13 levels were evaluated in paired serum and saliva specimens of 45 pSS patients (15 with NHL; pSS-associated NHL: SSL), 11 sicca-controls (sicca-complaining individuals with negative MSG biopsy and negative autoantibody profile), 10 healthy individuals (healthy-controls) and 6 non-SS-NHLs. CXCL13+-cells were measured in paired MSG-tissues of 22 of pSS patients studied (including 7 SSLs) and all sicca-controls. CXCL13 serum levels were significantly increased in pSS and SSL patients compared to sicca- and healthy-controls and were positively correlated with the CXCL13+-cell number and biopsy focus-score. Serum CXCL13 was significantly higher in pSS patients with GCs, rheumatoid factor, hypocomplementemia, high disease activity, NHL and in high-risk patients for NHL development. CXCL13 saliva levels were significantly increased in SSL patients (compared to non-SS-NHLs), patients with GCs and in high-risk for NHL patients. Univariate analysis revealed that CXCL13 serum, but not saliva, levels were associated with lymphoma, an association that did not survive multivariate analysis. Conclusively, our findings confirm that serum, but not saliva, levels of CXCL13 are associated with histologic, serologic and clinical features indicative of more severe pSS. Frontiers Media S.A. 2021-08-17 /pmc/articles/PMC8416055/ /pubmed/34484201 http://dx.doi.org/10.3389/fimmu.2021.705079 Text en Copyright © 2021 Chatzis, Goules, Stergiou, Voulgarelis, Tzioufas and Kapsogeorgou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chatzis, Loukas Goules, Andreas V. Stergiou, Ioanna E. Voulgarelis, Michael Tzioufas, Athanasios G. Kapsogeorgou, Efstathia K. Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title | Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title_full | Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title_fullStr | Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title_full_unstemmed | Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title_short | Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren’s Syndrome |
title_sort | serum, but not saliva, cxcl13 levels associate with infiltrating cxcl13+ cells in the minor salivary gland lesions and other histologic parameters in patients with sjögren’s syndrome |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416055/ https://www.ncbi.nlm.nih.gov/pubmed/34484201 http://dx.doi.org/10.3389/fimmu.2021.705079 |
work_keys_str_mv | AT chatzisloukas serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome AT goulesandreasv serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome AT stergiouioannae serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome AT voulgarelismichael serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome AT tzioufasathanasiosg serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome AT kapsogeorgouefstathiak serumbutnotsalivacxcl13levelsassociatewithinfiltratingcxcl13cellsintheminorsalivaryglandlesionsandotherhistologicparametersinpatientswithsjogrenssyndrome |